Analysts estimate that Coherus BioSciences will report an earnings per share (EPS) of $-0.34. Investors in Coherus ...

Coherus BioSciences, Inc. announced the completion of its strategic transformation to focus on innovative oncology during Q2 2025, highlighting encouraging Phase 1b data for CHS-114, an anti-CCR8 ...

(RTTNews) - Coherus BioSciences, Inc. (CHRS) Tuesday said it has agreed to buy back about $170 million of its 1.500% convertible senior subordinated notes due 2026 at its principal plus interest ...

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market ...

– Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –– Reduced secured and convertible debt by 90% from ...

Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.

“2023 will be a year of continued transformation for Coherus with significant value drivers including four anticipated product launches and multiple upcoming clinical catalysts,” said Denny Lanfear, ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Coherus BioSciences Inc. (CHRS) on Monday reported a loss of $56.6 million in its first quarter. The Redwood City, California-based company said ...

Coherus BioSciences (NASDAQ:CHRS) is gearing up to announce its quarterly earnings on Thursday, 2025-11-06. Here's a quick overview of what investors should know before the release. Analysts are ...

– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI ® net sales ...